Orgenesis Inc. (ORGS)
USD 2.4
(10.6%)
USD 2.4
(10.6%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -5.72 Million USD | -136.73% |
| 2022 | 15.58 Million USD | 112.27% |
| 2021 | 7.34 Million USD | 131.97% |
| 2020 | -22.96 Million USD | -251.69% |
| 2019 | 15.14 Million USD | 90.27% |
| 2018 | 7.95 Million USD | 142.44% |
| 2017 | 3.28 Million USD | 360.48% |
| 2016 | -1.26 Million USD | -39.07% |
| 2015 | -906 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 100.0% |
| 2008 | -500.00 USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -617 Thousand USD | 95.52% |
| 2024 Q2 | -749 Thousand USD | 52.67% |
| 2023 Q3 | -29 Thousand USD | -100.77% |
| 2023 Q1 | 4.32 Million USD | -68.39% |
| 2023 FY | -5.72 Million USD | -136.73% |
| 2023 Q2 | 3.74 Million USD | -13.37% |
| 2023 Q4 | -13.76 Million USD | -47351.72% |
| 2022 Q1 | 6.49 Million USD | 542.64% |
| 2022 FY | 15.58 Million USD | 112.27% |
| 2022 Q4 | 13.67 Million USD | 297.53% |
| 2022 Q3 | 3.44 Million USD | 322.08% |
| 2022 Q2 | -1.54 Million USD | -123.84% |
| 2021 Q4 | -1.46 Million USD | -194.59% |
| 2021 Q1 | 4.23 Million USD | 218.18% |
| 2021 FY | 7.34 Million USD | 131.97% |
| 2021 Q3 | 1.55 Million USD | -48.61% |
| 2021 Q2 | 3.02 Million USD | -28.74% |
| 2020 Q2 | 1.5 Million USD | -11.83% |
| 2020 Q1 | 1.7 Million USD | -73.53% |
| 2020 Q3 | -5.22 Million USD | -446.75% |
| 2020 Q4 | -3.58 Million USD | 31.33% |
| 2020 FY | -22.96 Million USD | -251.69% |
| 2019 Q3 | 2.8 Million USD | -3.01% |
| 2019 Q1 | 2.99 Million USD | 30.44% |
| 2019 Q2 | 2.88 Million USD | -3.54% |
| 2019 FY | 15.14 Million USD | 90.27% |
| 2019 Q4 | 6.45 Million USD | 130.3% |
| 2018 Q2 | 1.79 Million USD | 80.65% |
| 2018 FY | 7.95 Million USD | 142.44% |
| 2018 Q3 | 2.87 Million USD | 60.55% |
| 2018 Q4 | 2.29 Million USD | -20.19% |
| 2018 Q1 | 992 Thousand USD | -32.52% |
| 2017 Q3 | 695 Thousand USD | -40.6% |
| 2017 Q4 | 1.47 Million USD | 111.51% |
| 2017 FY | 3.28 Million USD | 360.48% |
| 2017 Q2 | 1.17 Million USD | 2307.55% |
| 2017 Q1 | -53 Thousand USD | 89.14% |
| 2016 FY | -1.26 Million USD | -39.07% |
| 2016 Q4 | -488 Thousand USD | -2540.0% |
| 2016 Q3 | 20 Thousand USD | 102.4% |
| 2016 Q2 | -832 Thousand USD | -2180.0% |
| 2016 Q1 | 40 Thousand USD | 110.99% |
| 2015 Q2 | -152.55 Thousand USD | 81.72% |
| 2015 Q3 | -389.52 Thousand USD | -155.33% |
| 2015 FY | -906 Thousand USD | 0.0% |
| 2015 Q4 | -363.91 Thousand USD | 6.57% |
| 2015 Q1 | -834.7 Thousand USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 100.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 FY | -500.00 USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 3495.853% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -2190.0% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -939.02% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -3116.292% |
| Better Therapeutics, Inc. | -2.72 Million USD | -109.784% |
| Calithera Biosciences, Inc. | -1.38 Million USD | -313.357% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 1454.35% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 75.021% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | -460.454% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 19.275% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -2110.425% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -10763.79% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | -104.764% |
| Molecular Templates, Inc. | 50.39 Million USD | 111.36% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -4699.028% |
| NexImmune, Inc. | -1.02 Million USD | -458.552% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 77.678% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -124329.472% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 119.481% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -1072.401% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -2367.672% |
| Trevena, Inc. | 1.45 Million USD | 493.471% |
| Vaxxinity, Inc. | -2.23 Million USD | -156.267% |
| Vaccinex, Inc. | -16 Million USD | 64.228% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -1063.618% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 49410.939% |